

# KELLERHALS CARRARD ADVISES BIOGNOSYS ON ITS PARTNERSHIP WITH BRUKER

*Posted on 12 January 2023*



**Category:** [Deal & transactions](#)

**Tags:** [Dario Silberschmidt](#), [Karim Maizar](#), [Kellerhals Carrard](#), [michele remund](#), [Nicolas Mosimann](#), [Sarah Schneider](#), [Slider](#), [Vanessa Witschi](#)



**Biognosys** and **Bruker Corporation** announced a strategic partnership, in which **Bruker** has made a majority-ownership investment in the company. Several of Biognosys' earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys.

Biognosys mass spectrometry-based proteomics solutions help CRO services and proteomics software customers in uncovering connections between genome, transcriptome, and phenotype to explore the static and dynamic nature of disease biology. The collaboration is expected to create unique synergies between Biognosys' versatile portfolio of proprietary proteomics services, software and kits, and Bruker's pioneering timsTOF platform. As a result of the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the United States.

[Kellerhals Carrard](#) advised Biognosys and the majority of its shareholders on this transaction. The team was comprised of **Karim Maizar** (partner, m&a/vc, pictured left), **Nicolas Mosimann** (partner, m&a/vc, pictured right), **Michèle Remund** (tax) as well as **Dario Silberschmidt** (M&A/VC), **Vanessa Witschi** (m&a/tax) and **Sarah Schneider** (m&a/vc).